Biogen discontinues Apellis programs post $5.6B acquisition, reallocating resources to Empaveli and Syfovre. U.S. begins ...

Biogen Canada Inc. is disappointed that negotiations with the pan-Canadian Pharmaceutical Alliance (pCPA) for SKYCLARYS™ ...

From persevering with a tricky Alzheimer’s program to securing a late-stage CD38-directed antibody and posting encouraging lupus data, Biogen has remained in the news recently—and that’s no accident.

BOSTON, June 8 (Reuters) - Biogen (BIIB.O), opens new tab has agreed to pay $18.9 million to resolve a lawsuit alleging that it misled investors about the commercial readiness of the pharmaceutical ...

Biogen has announced that salanersen has been given the US FDA Breakthrough Therapy Designation to treat spinal muscular atrophy (SMA).Salanersen is an investigational novel antisense oligonucleotide ...

SMA is a rare, genetic neuromuscular disease leading to progressive muscle weakness due to the loss of motor neurons. Credit: Panchenko Vladimir / Shutterstock.com. Biogen has received the ...

Salanersen, a new Biogen treatment for SMA, was awarded breakthrough therapy status by the U.S. Food and Drug Administration. This potent therapy, similar to Spinraza, requires fewer doses (once ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Apellis Pharmaceuticals Inc. shareholders who sued the drugmaker’s leadership for allegedly concealing the safety risks of a blindness-prevention drug are dropping their suit following Biogen Inc.'s ...

UCB and Biogen (BIIB) on Monday said that their investigational drug dapirolizumab pegol met the primary endpoint in a phase 3 trial for systemic lupus erythematosus, with 50% of patients achieving a ...